LAQ Comprehensive

MD Dermatology NMC syllabus ~5 min read Recent advances last updated on 2026-06-20

Classification of Antihistamines

H₁–H₄ antagonists · generations · chemical classes · newer agents and their advantages

Past RGUHS · 2 RGUHS2023 RGUHS2017

Introduction

Definition — Antihistamines are drugs that antagonise histamine at its receptors; the unqualified term means the H₁ antihistamine, the mainstay of urticaria and histamine-mediated pruritus.
Histamine acts through four GPCR subtypes — H₁, H₂, H₃, H₄ — so the antihistamine family spans four pharmacological targets, of which H₁ and H₂ are in routine dermatologic use.
More than 45 H₁ antihistamines exist worldwide; in DVL they treat urticaria, angioedema, pruritus, drug/food allergy, mastocytosis and allergic rhinitis/conjunctivitis.

Classification

Axis A — by receptor target — H₁ antagonists (conventional antihistamines) · H₂ antagonists (cimetidine, ranitidine, famotidine, nizatidine) · H₃ ligands (autoreceptor; CNS) · H₄ ligands (investigational antipruritic).
Axis B — H₁ agents by generation — First-generation (sedating, non-selective, short-acting) vs second-generation (non-sedating, H₁-selective, long-acting); a so-called third-generation (active metabolites/enantiomers) is not accepted as a distinct class.
Axis C — by chemical structure — Ethanolamines (diphenhydramine) · ethylenediamines (pyrilamine) · alkylamines (chlorpheniramine) · piperazines (hydroxyzine, cetirizine) · piperidines (cyproheptadine, loratadine, fexofenadine) · phenothiazines (promethazine) · phthalazinones (azelastine).

Histamine receptors and their antihistamine relevance (basis of the receptor-target classification)

Receptor	G-protein / messenger	Key effects	Antagonist examples
H₁	Gq → IP₃/DAG, ↑Ca²⁺	Itch, wheal/flare, vasodilation, bronchoconstriction, CNS arousal	Cetirizine, fexofenadine, chlorpheniramine
H₂	Gs → ↑cAMP	Gastric acid; minor cutaneous vasodilation	Cimetidine, ranitidine, famotidine
H₃	Gi → ↓cAMP	Presynaptic autoreceptor — ↓ histamine release	Thioperamide, pitolisant (CNS)
H₄	Gi → ↓cAMP	Mast-cell/eosinophil chemotaxis, itch	JNJ-39758979, toreforant, adriforant (investigational)

Figure 1 — Classification of antihistamines: receptor target, generation and chemical class

Figure 2 — The four histamine receptors (H₁–H₄) and their antihistamine relevance

Mechanism of action

Inverse agonism — H₁ (and H₂) antihistamines are inverse agonists — they bind and stabilise the inactive receptor conformation, down-regulating its constitutive activity (not simple competitive blockade).
Anti-inflammatory effect — Via the H₁ receptor they also ↓ pro-inflammatory cytokines (TNF-α, IL-6, IL-8), ↓ adhesion molecules (ICAM-1, VCAM-1) and ↓ eosinophil chemotaxis — most evident at higher doses.
Palliative only — They block the effects of released histamine but do not prevent histamine release or the antigen–antibody reaction.

First-generation H₁ antihistamines

Defining features — Lipophilic → cross the blood–brain barrier (sedation); non-selective → anticholinergic, anti-α-adrenergic, anti-serotonergic, local-anaesthetic actions; short-acting (q4–8h).
By chemical class (examples) — Ethanolamine — diphenhydramine, dimenhydrinate; piperidine — cyproheptadine (antiserotonin, appetite gain); phenothiazine — promethazine (antiemetic; avoid <2 y); alkylamine — chlorpheniramine (least sedating); piperazine — hydroxyzine (antipruritic, anxiolytic).
Caveats — Reduce REM sleep and next-day performance, increase accidents; the GA²LEN position paper flags avoidable risk. Contraindicated in narrow-angle glaucoma, BPH, with MAO inhibitors.

Second-generation antihistamines and their advantages

Definition — Post-1980 H₁ blockers that are non-/low-sedating, H₁-selective (minimal anticholinergic effect) and long-acting (once daily); some carry additional antiallergic actions (↓ leukotrienes, PAF, cytokines).
Newer agents (examples) — Fexofenadine, loratadine, desloratadine, cetirizine, levocetirizine, and the newest — ebastine, bilastine, rupatadine, mizolastine, azelastine, olopatadine.
Advantages over first-generation — No/low sedation and no psychomotor impairment (driving not contraindicated); no anticholinergic effects; once-daily dosing improves compliance; no potentiation of alcohol/benzodiazepines; cardiac-safe (current agents lack the QT risk that withdrew terfenadine/astemizole).
Metabolite/enantiomer chains — Hydroxyzine → cetirizine → (R-enantiomer) levocetirizine; loratadine → desloratadine; terfenadine → fexofenadine (these are the basis of the contested third-generation label).
Dual-mechanism newer agents — Rupatadine = H₁ + PAF antagonist; olopatadine / azelastine / ketotifen = H₁ antagonist + mast-cell stabiliser; bilastine = no CYP metabolism, no food/CYP interaction.
Caveat — Cetirizine and levocetirizine (piperazines) retain mild sedation in ~10–15%; fexofenadine and loratadine/desloratadine are the least sedating.

Figure 3 — First- vs second-generation H₁ antihistamines

Pharmacological actions and dermatological uses

Chronic spontaneous urticaria — Second-generation non-sedating H₁ antihistamines are first-line; effective in ~50%. Stepwise ladder: standard dose → up-dose up to 4× → add omalizumab/ciclosporin.
Pruritus — Useful where itch is histamine-mediated (urticaria, mastocytosis, insect bites); first-generation agents relieve nocturnal itch chiefly through sedation.
Atopic dermatitis — Weak/ambiguous evidence — benefit is mainly the soporific effect; AAD discourages routine use; reserve for AD with concomitant urticaria/rhinitis.
Other uses — Doxepin (TCA, dual H₁/H₂, 800× diphenhydramine) for refractory urticaria/pruritus; H₂ antagonists as weak adjuncts; antihistamines as adjuncts (not primary) in anaphylaxis — adrenaline is first-line.

Figure 4 — Step-wise management of chronic urticaria (EAACI/GA²LEN/EDF/WAO)

Adverse effects and precautions

First-generation — Sedation, impaired cognition/psychomotor performance, paradoxical excitation in children; anticholinergic (dry mouth, urinary retention, blurred vision, constipation); postural hypotension; overdose mimics belladonna poisoning (excitation, convulsions).
Second-generation — Generally well tolerated; mild sedation with cetirizine/levocetirizine; rare headache/GI upset.
Cardiotoxicity (historical) — Terfenadine and astemizole withdrawn for QT prolongation/torsades (K⁺-channel block, worsened by CYP3A4 inhibitors); current agents are safe.
Pregnancy/lactation — Chlorpheniramine and cetirizine/loratadine preferred (category B); avoid first-generation in lactation (sedation, ↓ milk).

Recent advances

H₄-receptor antagonists — JNJ-39758979 showed efficacy in atopic dermatitis/pruritus but was terminated for agranulocytosis; toreforant (no agranulocytosis) and adriforant (ZPL-3893787) are the clinical-stage H₄ antipruritics. PMID 28233185
H₄R itch mechanism — The H₄ receptor with TRPV1 mediates cadaverine-induced itch — reinforcing H₄R as an antipruritic target distinct from H₁. PMID 39079948
H₃ ligand pitolisant — The only marketed H₃ inverse agonist — approved for narcolepsy, no dermatologic indication; betahistine remains the H₁-analogue for Ménière's. PMID 39186901
Dupilumab for CSU — Anti-IL-4Rα biologic — first new targeted CSU therapy in over a decade (LIBERTY-CSU CUPID); FDA-approved April 2025 (≥12 y), extended to children 2–11 y April 2026. FDA 2025-Apr · PMID 41706458
Remibrutinib (oral BTK inhibitor) — FDA first approval 30 Sep 2025 for antihistamine-refractory CSU — an oral step-up beyond antihistamine up-dosing. PMID 41559488
Barzolvolimab (anti-KIT) — Mast-cell-depleting mAb gave 71% well-controlled and 57% complete response in antihistamine-refractory CSU (phase 1b). PMID 40415544
Guideline — EAACI/GA²LEN/EuroGuiDerm/APAAACI 2022 — second-generation antihistamines first-line, up-dose 4×, then omalizumab; first-generation agents not recommended for routine CSU. Bilastine approved by DCGI/CDSCO in India. PMID 35092619 · DCGI

Mnemonic — receptor G-protein coupling

"1-Q, 2-S, 3/4-i": H₁ = Gq (IP₃/DAG/Ca²⁺) · H₂ = Gs (↑cAMP) · H₃ and H₄ = Gi (↓cAMP). First-gen sedation classes (KDT): Highly — diphenhydramine, dimenhydrinate, promethazine, hydroxyzine.

Clinical pearls

Second-generation non-sedating H₁ antihistamine is the single best answer to "drug of choice for chronic urticaria"; up-dose to 4× before escalating.
Cetirizine = metabolite of hydroxyzine; it concentrates in skin → superior in urticaria/AD but mildly sedating.
Terfenadine and astemizole are the classic "withdrawn for torsades" antihistamines — a favourite viva point.
"No third-generation antihistaminic" — international consensus; the metabolite/enantiomer agents stay second-generation.

First- vs second-generation H₁ antihistamines (the high-yield comparison)

Feature	First-generation	Second-generation
BBB penetration / sedation	High / sedating	Low / non-sedating
H₁ selectivity	Low (anticholinergic, anti-α, anti-5HT)	High (selective)
Duration / dosing	Short, q4–8h	Long, once daily
Extra antiallergic action	None	↓ LT, PAF, cytokines (some)
Prototype	Diphenhydramine, chlorpheniramine	Fexofenadine, cetirizine, bilastine

References and further reading

IADVL — Textbook of Dermatology, 5e — Ch.96 Antipruritic Agents; Ch.37 Diagnosis and Management of Urticaria.
Fitzpatrick — Dermatology in General Medicine, 9e — Ch.189 Antihistamines.
Wolverton — Comprehensive Dermatologic Drug Therapy, 4e — Ch.32 Antihistamines.
Recent Advances updated on — 2026-06-20 — PubMed, US-FDA, CDSCO/DCGI, EAACI/GA²LEN 2022.